• Dry Cracked Skin
  • General Dermatology
  • Impetigo
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Surgery
  • Melasma
  • NP and PA
  • Anti-Aging
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Inflamed Skin

NICE recommends adalimumab as treatment for plaque psoriasis

Article

National report - The National Institute for Health and Clinical Excellence (NICE) is recommending adalimumab as a treatment for adults with plaque psoriasis, redOrbit reports.

National report

- The National Institute for Health and Clinical Excellence (NICE) is recommending adalimumab as a treatment for adults with plaque psoriasis, redOrbit reports.

NICE is recommending the drug for those whom anti-tumor necrosis factor treatment is being considered and when the following criteria are both met: The disease is severe as defined by a total Psoriasis Area Severity Index of 10 or more and a Dermatology Life Quality Index of more than 10, and when the psoriasis has not responded to standard systemic therapies or if the person is intolerant of or has a contraindication to these treatments.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.